IDO1 and melanoma: To study the association of IDO+ melanoma cell coverage with clinicopathological parameters and survival, samples were divided into two groups; IDO-negative and IDO-positive tumors, which represented samples that contained less than 1% or more than 1% IDO+ tumor cells of all melanoma cells, respectively.